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Previews
regard, it is notable that a thrombin binding DNA ap-Aptamer Rivalry
tamer has been found to confer significant anticoagulant
properties in an animal model [4], and a chemically modi-
fied RNA aptamer for vascular endothelial growth factor
(VEGF) has been shown to inhibit the growth of new
blood vessels in a rat model [5].A controllable, intracellular RNA aptamer could be an
Many of the above-mentioned experiments haveinvaluable therapeutic or discovery reagent. A report
made use of methods to constitutively express aptamerspublished in this journal shows that aptamer behavior
within cells to allow stable phenotypes to be manifested.can be regulated by a small molecule, paving the way
However, it has been recognized that this technologyfor the development of more sophisticated ligand-reg-
may prove especially useful if it were possible to turnulated aptamers.
the intracellular aptamer on and off on demand. This
would be a powerful tool to study the developmental
Since 1990, when the now familiar technology of in vitro programs of different cells and organisms. One possible
selection, SELEX (systematic evolution of ligands by approach toward such flexibility might be to regulate
expontential enrichment), was first reported in the scien- the production of the aptamer by placing its expression
tific literature, there has been a sense of excitement under the control of an inducible promoter. An alterna-
about the vast potential of this methodology. In its early tive approach would be to express the aptamer intracel-
stages, SELEX was used primarily to select novel, anti- lularly at high levels but in a quiescent state, from which
body-like affinity reagents made from RNA and DNA it could then be activated or rescued on demand. A
(aptamers) as well as new RNA and DNA enzymes (ribo- paper by Vuyisich and Beal published in this issue of
zymes and DNAzymes). Astonishingly, some of these Chemistry & Biology [6] reports on a prototypical
enzymes had catalytic activities not found in living sys- scheme for precisely this latter mechanism.
tems. These initial success stories sparked the tantaliz- The goal set out by Vuyisich and Beal was to select
ing idea that the ever-growing list of aptamers and nu- for aptamers that not only bound a target protein tightly
cleic acid enzymes may eventually be used within living and specifically (thus inhibiting its cellular function) but
cells and organisms both in therapeutics and as tools which also bound specifically to a small molecule ligand.
for dissecting fundamental cellular processes. Finally, The protein chosen by Vuyisich and Beal for their proof-
in 2002, we now find ourselves firmly in that anticipated of-concept experiment was a DNA repair enzyme, for-
realm. Several potentially therapeutic ribozymes are cur- mamidopyridine glycosylate (Fpg), and the ligand the
rently being tested in clinical trials (reviewed in [1]), and
common antibiotic neomycin. These two compounds
the dream of using both aptamers and ribozymes to
were chosen because they both naturally have low-level
probe cellular pathways is now a reality.
affinities for binding nucleic acids. The selection proce-
A key milestone on the path toward developing clini-
dure itself was both simple and elegant. First, foldedcally useful RNA and DNA was the finding that it is
RNA molecules from a random-sequence RNA librarypossible to express aptamers and ribozymes within cells
were selected for their ability to bind Fpg protein thatat sufficiently high levels to influence their phenotype.
had been immobilized to a column. The next, innovative,This was first demonstrated by Werstuck and Green in
step, eluting the bound RNA with a solution containing1998 [2], who showed that two different RNA aptamers
neomycin, ensured that RNAs were selected that boundthat specifically bound an antibiotic (either Kanamycin
Fpg in the absence of neomycin but released Fpg (effec-A or Tobramycin) could be robustly expressed in E. coli
tively activating the protein) in the presence of the antibi-cells, conferring specific antibiotic resistance to those
otic. Analysis of RNA clones obtained following manycells. Further, the authors showed that incorporation of
iterations of this selection cycle and footprinting experi-an antibiotic-specific aptamer into the 5 untranslated
ments carried out on individual clones revealed physi-region of a messenger RNA resulted in repression of
cally overlapping aptamer elements for binding Fpg andtranslation of that message in a specific antibiotic-
binding neomycin. This provides a physical basis fordependent manner. Since that groundbreaking report,
understanding the ability of neomycin to disrupt theRNA aptamers targeted against various proteins have
aptamer-Fpg interaction. Fundamentally, competitionbeen expressed in different cells (with appropriate ex-
between the overlapping aptamer elements for bindingpression vectors dispatching the aptamer RNA to differ-
their respective ligand decides the functional state ofent cellular compartments and locations). Using this ap-
the RNA molecule. Interestingly, Vuyisich and Beal em-proach, aptamer-generated phenotypes have been
phasize that future development of this technology willobserved in diverse eukaryotic cell types as well as in
utilize not only known cytotoxic agents such as neomy-transformed Drosophila melanogaster. The proteins that
cin but also “neutral” or “unobtrusive” small moleculehave been targeted by this method are wide ranging
ligands, which ideally would enjoy both high permeabil-and include RNA polymerase II in S. cerevisiae, the RNA
ity into cells and minimum intrinsic interaction with cellu-splicing factor B52 in Drosophila, the transcriptional reg-
lar processes and pathways.ulator NFB expressed in yeast, and a domain of the
2 subunit of human integrin (reviewed in [3]). In this Vuyisich and Beal’s demonstration of a ligand-regu-
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zoal parasites of the genus Plasmodium (with P. falci-
parum the cause of fatal cases) [5]. They have a complex
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Discovering Antimalarials:
a New Strategy life cycle involving liver and blood stages in the human
host, where asexual reproduction occurs, and a stage
in the vector mosquito (Anopheles genus), where sexual
Recent discoveries have uncovered some key pro- reproduction occurs [5]. Symptoms and pathology are
cesses that occur in the food vacuole of the malarial associated entirely with the blood stage, during which
parasite. Consequently, new families of potential anti- the parasite is located within the red blood cell of the
malarials that inhibit HRP-2, a hitherto unexplored host [5]. During this part of the life cycle, the parasite
drug target, were identified using a novel screening ingests hemoglobin into a specialized acidic compart-
method. ment called a food vacuole. The hemoglobin is proteolyt-
ically digested into small peptides that ultimately supply
Malaria is one of the world’s leading killer infectious the parasite with amino acids [6] (although intriguingly,
diseases. Although almost a third of the Earth’s popula- these nutrients appear to be oversupplied [7]). Proteoly-
tion is considered to be at risk from this disease, about sis is carried out by four aspartic proteases, namely
90% of infections and deaths occur in Africa [1], contrib- plasmepsins I, II, and IV, and histo-aspartic protease
uting significantly to underdevelopment and poverty on (HAP) [8], three cysteine proteases (falcipains) [9], and
this continent [2]. The reasons for the current severity a zinc protease (falcilysin) [10]. All of these represent
of the malaria problem are multifaceted, but among them potential targets for antimalarials (see Figure) and are
is the occurrence of drug-resistant strains of parasite. currently the subject of intense investigation. Digestion
Most notable in this regard is parasite resistance to of hemoglobin releases heme [iron(II)protoporphyrin IX,
chloroquine, which is now almost universal. In the past, Fe(II)PPIX] into the food vacuole, where it is oxidized to
this drug, having several excellent properties, became hematin [H2O-Fe(III)PPIX] [6]. Heme is another possible
the mainstay of treatment and was a key component of drug target and has been implicated in the mode of
malaria control strategies. In particular, chloroquine was action of endoperoxide antimalarials, such as artemes-
highly effective against the parasite, had very few ad- inin, which have been proposed to form radical adducts
verse side effects, was safe for use in pregnancy and with heme that act against the parasite [11]. Hematin
young children, and was very cheap [3]. Its loss has is believed to be the target of chloroquine and other
been a major setback [4]. The challenge now is to find quinoline antimalarials, and there is evidence sug-
new compounds with antimalarial activity that can be gesting that these drugs act by preventing the detoxifi-
developed into drugs that are cheap enough for use in cation of hematin (see Figure) [12], essentially all of
poor third world countries. which is normally converted to a very insoluble micro-
A positive development over the last decade has been crystalline dimer of Fe(III)PPIX called hemozoin (or ma-
the considerable increase in our understanding of pro- laria pigment) [13]. Chemically, hemozoin is identical
in composition [14] and structure [15] to -hematin, acesses occurring within the parasite that are relevant to
the mode of action of current antimalarials and which synthetic product that can easily be prepared from a
solution of hematin.provide targets or potential targets for new antimalarial
compounds. The causative agents of malaria are proto- The mechanism of hemozoin formation in the parasite
